Lipopolysaccharide-specific acyloxyacyl hydrolase

Details Lipopolysaccharide-specific acyloxyacyl hydrolase Lipopolysaccharide-specific acyloxyacyl hydrolase

1989-03-15

1991-05-07

Weimar, Elizabeth C.

Chemistry: molecular biology and microbiology

Enzyme , proenzyme; compositions thereof; process for...

Hydrolase

435 84, 514 53, 514 54, 536 53, 424 9461, C12N 918, A61K 31715, C12P 1926

Patent

active

050136615

ABSTRACT:
An acyloxyacyl hydrolase from the human promyelocyte cell line HL-60 has been found to specifically hydrolyze fatty acids from their ester linkages to hydroxy groups of 3-hydroxyfatty acids, the latter being being bound in turn to lipopolysaccharide glycosaminyl residues. The hydrolyzed fatty acids may include dodecanoic acid, tetradecanoic acid and hexadecanoic acid. This enzyme showed a molecular weight by gel exclusion chromatography between about 50,000 Daltons and about 70,000 Daltons, and a molecular weight by polyacrylamide gel electrophoresis with sodium dodecylsulphate, using reduced molecular weight standards, of approximately 54,000 to 60,000 Daltons.
Altered bacterial lipopolysaccharide substantially without fatty acids bound in ester linkage to hydroxy groups of 3-hydroxyfatty acids covalently linked to a glucosaminyl moiety of lipopolysaccharide lipid A are produced. Since the structure of the lipid A moiety is highly conserved, acyloxyacyl hydrolase may act on lipopolysaccharide of many different pathogenic bacteria (for example Salmonella, Escherichia, Hemophilus, and Neisseria).
Such altered bacterial lipopolysaccharide, having toxicity reduced more than immunostimulatory activity, may be therapeutically useful: (1) as vaccines to prevent Gram-negative bacterial diseases by inducing antibodies to lipopolysaccharide O-polysaccharide or R-core antigens, (2) as antidotes to treat or prevent Gram-negative bacterial sepsis ("septic shock"), or (3) as adjuvants to enhance formation of antibodies to other antigens. the acyloxyacyl hydrolase itself may be prophylactically or therapeutically useful to detoxify endogenous lipopolysaccharide in patients with Gram-negative bacterial diseases. The enzyme may also be used to remove toxic lipopolysaccharide from therapeutic injectants.

REFERENCES:
patent: 4057685 (1977-11-01), McIntire
patent: 4148877 (1979-04-01), Choay et al.
patent: 4185090 (1980-01-01), McIntire
patent: 4242270 (1980-12-01), Ayme et al.
patent: 4435386 (1984-03-01), Ribi et al.
patent: 4436727 (1984-03-01), Ribi
patent: 4436728 (1984-03-01), Ribi et al.
patent: 4505899 (1985-03-01), Ribi et al.
patent: 4505900 (1985-03-01), Ribi et al.
patent: 4663306 (1987-05-01), Cantrell
patent: 4677194 (1987-06-01), Hao
patent: 4719202 (1988-01-01), van Boeckel et al.
Kotani, et al. (1985), Infect. Immun., 49:225-237.
Takada, et al. (1985), Infect. Immun., 48:219-227.
Homma, et al. (1985) J. Biochem., 98:395-406.
Galanos, et al. (1984), Eur. J. Biochem., 140:221-227.
Rosner, et al. (1979), J. Biol. Chem., 254:5926-5933.
Gimber and Rafter (1969), Arch. Biochem. Biophys., 135:14-20.
Munford and Hall (1985), Infect. Immun., 48:464-473.
Freudenberg, et al. (1984), Rev. Inf. Dis., 6:483-487.
Kotani, et al. (1984), Infect. Immun., 485:293-296.
Sutherland (1977), "Surface Carbohydrates of the Prokaryotic Cells", pp. 209-245.

Affiliated with

Also associated with

Rating

Lipopolysaccharide-specific acyloxyacyl hydrolase does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Lipopolysaccharide-specific acyloxyacyl hydrolase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lipopolysaccharide-specific acyloxyacyl hydrolase will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-939202